Xtant Medical Holdings, Inc. (XTNT)
Oxford Ledge is still expanding full research coverage of XTNT. A live quote, fundamentals, and analysis are available in the app; the SEC-sourced material below is what we currently have indexed here.
Business summary
Xtant Medical develops and sells bone graft materials and spinal implants to surgeons across the United States and select international markets.
SEC filings
- DEF 14A Proxy statement for shareholder vote 2026-06-23
- 10-Q Quarterly financial report (unaudited) 2026-05-13
- 8-K Results of operations / financial condition; Other material event; Financial statements and exhibits 2026-05-13
- 8-K Regulation FD disclosure; Other material event; Financial statements and exhibits 2026-04-13
- 10-K Annual financial report with audited statements 2026-03-31
Source: SEC EDGAR.
Annual results
5 years of annual figures for XTNT, as filed with the SEC. Figures are as reported and are not restated or adjusted.
| Fiscal year | Revenue | Net income | EPS (diluted) |
|---|---|---|---|
| 2025 | $133.9M | $5.0M | $0.03 |
| 2024 | $117.3M | -$16.4M | -$0.12 |
| 2023 | $91.3M | $660,000 | $0.01 |
| 2022 | $58.0M | -$8.5M | -$0.09 |
| 2021 | $55.3M | -$4.8M | -$0.06 |
Source: SEC EDGAR (XBRL company facts). Full statements and ratios in the terminal.
Insider activity
5 recent insider (SEC Form 4) filings on record for XTNT. View the transactions in the terminal.
Source: SEC EDGAR (Form 4).
- Open XTNT in the Oxford Ledge terminal — live quote, chart, and analysis in the app.
- Browse the covered-stock index
- Learn to analyze stocks yourself
The material above is drawn from public SEC EDGAR filings and is provided for educational purposes, not as investment advice. Live pricing and fundamentals are available in the terminal.